Anti-idiotypic antibodies which neutralise the inhibitory...

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/42 (2006.01) A61K 39/395 (2006.01) A61P 7/04 (2006.01) C12N 5/20 (2006.01) C12N 15/13 (2006.01) G01N 33/53 (2006.01)

Patent

CA 2734549

The present invention relates to an anti-idiotypic monoclonal antibody directed against a Factor VIII- inhibiting antibody which binds to the C1 domain of Factor VIII, and also relates to a cell line producing this anti-idiotypic monoclonal antibody, to the use of this anti-idiotypic monoclonal antibody as a medicament, and more particularly to the use thereof for the manufacture of a medicament for the treatment of haemophilia A.

La présente invention se rapporte à un anticorps monoclonal anti-idiotypique dirigé contre un anticorps inhibiteur du facteur VIII se liant au domaine C1 du facteur VIII, ainsi qu'à une lignée cellulaire produisant cet anticorps monoclonal anti-idiotypique, à l'utilisation de cet anticorps monoclonal anti-idiotypique comme médicament, et plus particulièrement à son utilisation pour la fabrication d'un médicament destiné au traitement de l'hémophilie A.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Anti-idiotypic antibodies which neutralise the inhibitory... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-idiotypic antibodies which neutralise the inhibitory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-idiotypic antibodies which neutralise the inhibitory... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1851809

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.